Bristol Myers Squibb (BMY) Net Cash Flow Growth (5y) (2014 - 2026)

Bristol Myers Squibb (BMY) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 30.48%
Dec 31, 2025 -2.08%
Sep 30, 2025 51.01%
Jun 30, 2025 -16.89%
Mar 31, 2025 -33.27%
Dec 31, 2024 16.51%
Sep 30, 2024 -6.31%
Jun 30, 2024 -16.47%
Mar 31, 2024 -47.93%
Dec 31, 2023 20.65%
Sep 30, 2023 -31.87%
Jun 30, 2023 -14.98%
Mar 31, 2023 -26.37%
Dec 31, 2022 10.18%
Sep 30, 2022 -35.43%
Jun 30, 2022 -28.26%
Mar 31, 2022 -37.52%
Dec 31, 2021 -10.48%
Sep 30, 2021 38.64%
Jun 30, 2021 -27.67%